Establishment Labs Holdings Inc. $ESTA Stock Sold by JW Asset Management LLC

JW Asset Management LLC trimmed its holdings in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 9.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,451,067 shares of the company’s stock after selling 241,789 shares during the period. Establishment Labs accounts for approximately 65.3% of JW Asset Management LLC’s holdings, making the stock its largest holding. JW Asset Management LLC owned approximately 8.22% of Establishment Labs worth $157,285,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of ESTA. Arizona State Retirement System increased its stake in shares of Establishment Labs by 5.6% in the second quarter. Arizona State Retirement System now owns 5,057 shares of the company’s stock valued at $434,000 after buying an additional 268 shares in the last quarter. HighTower Advisors LLC lifted its position in Establishment Labs by 3.2% during the 2nd quarter. HighTower Advisors LLC now owns 9,517 shares of the company’s stock worth $817,000 after buying an additional 293 shares in the last quarter. Integrated Wealth Concepts LLC bought a new stake in Establishment Labs during the 2nd quarter worth about $32,000. KBC Group NV bought a new stake in Establishment Labs during the 1st quarter worth about $28,000. Finally, Northwestern Mutual Wealth Management Co. bought a new stake in Establishment Labs during the 2nd quarter worth about $43,000. Institutional investors own 72.91% of the company’s stock.

Wall Street Analysts Forecast Growth

ESTA has been the subject of several research reports. Canaccord Genuity Group set a $105.00 price objective on shares of Establishment Labs in a research report on Thursday, August 6th. TD Cowen reduced their target price on shares of Establishment Labs from $117.00 to $95.00 and set a “buy” rating on the stock in a research report on Monday, October 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research note on Monday, September 21st. Stifel Nicolaus started coverage on shares of Establishment Labs in a report on Wednesday, October 14th. They issued a “buy” rating and a $85.00 price target for the company. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Establishment Labs from $84.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Establishment Labs currently has a consensus rating of “Moderate Buy” and an average price target of $95.00.

Establishment Labs Stock Down 2.9%

Shares of ESTA stock opened at $68.62 on Friday. The firm’s 50 day moving average price is $66.07 and its two-hundred day moving average price is $72.34. The company has a quick ratio of 2.52, a current ratio of 3.57 and a debt-to-equity ratio of 17.17. Establishment Labs Holdings Inc. has a 52-week low of $53.16 and a 52-week high of $97.59.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings data on Friday, October 30th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.09). The company had revenue of $71.99 million for the quarter, compared to analyst estimates of $66.81 million. Establishment Labs had a negative return on equity of 196.38% and a negative net margin of 14.56%. The firm’s revenue for the quarter was up 33.8% on a year-over-year basis. During the same period last year, the firm earned ($0.38) earnings per share. As a group, equities analysts forecast that Establishment Labs Holdings Inc. will post -1.18 EPS for the current year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc. is a medical technology company focused on breast health and aesthetics. Founded in 2004 by Juan José Chacón-Quirós, the Costa Rica-based company develops and manufactures products for breast augmentation and reconstruction. Its product portfolio includes Motiva breast implants, offered in different shapes and designs, as well as related technologies and products for plastic and reconstructive surgery. The company also develops solutions intended to support surgical procedures and patient care.